Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Candesartan, Atorvastatin, and Amlodipine
NCT04245046Phase 1Completed
- Sponsor
- Midas Pharma
- Start
- Jan 2019
- Primary completion
- Feb 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of candesartan cilexetil, atorvastatin and amlodipine in hypertension (HTN) and hypercholesterolemia, sponsored by Midas Pharma. Primary endpoints: Maximum Plasma Concentration at Steady State and Area Under the Plasma Concentration Curve. Started Jan 2019; status: completed.
02
Drugs
candesartan cilexetilatorvastatinamlodipine
03
Conditions
hypertension (HTN)hypercholesterolemia
Beyond the preview
Go deeper on NCT04245046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04245046.